Roy de Souza

Last updated
Roy de Souza
Born1970
Nairobi, Kenya
NationalityIndian
Education University of Oxford (M.S. in Engineering)
Kellogg Business School (M.B.A.)
OccupationEngineer
Known forCancer research (AI Drug Discovery Per Patient)
Parent

Roy de Souza (born 1970) is an Indian engineer and writer. He is the co-founder of technology company ZEDO and medical technology company BreakBio. [1] [2] In 2022, he was a TEDx speaker. [3] In May of 2023 he and his late wife were honored by the American Cancer Society http://womenandwellness.com for Roy's work in personalized medicine.

Contents

Education

He earned a master's degree in engineering from the University of Oxford and an MBA from Kellogg Business School. [1]

Career

De Souza served as a strategy consultant at the COBA Group, a strategy consulting boutique based in the UK. [4] [5]

De Souza also worked in product management for the Elon Musk-founded web software company Zip2. [6]

De Souza founded technology company ZEDO in 1999. [1] [7] In 2006, he founded the company Zebo, an offshoot of ZEDO focused on allowing users to catalog personal possessions and shop for similar items. [8] [9] [10] De Souza launched online ad exchange ZINC India in 2011, which was originally ZEDO's ad exchange platform in India before becoming a separate company. [11] [12] [13] He served as the ZEDO's CEO and oversaw the company as it transitioned into a subsidiary of Discovery following its acquisition by Discovery, Inc. in 2021. [14] [15] [16]

In 2022, he was a TEDx speaker, talking about vaccines to prevent cancer. . [3]

Cancer research

After his wife, Aisha de Sequeira's cancer diagnosis, de Souza became involved in vaccine research to develop a personalized vaccine for her cancer. [1] De Souza went on to co-found medical technology company BreakBio, basing the company in Boston, Massachusetts. [1] [2] [17] BreakBio develops personalized vaccines [2] and AI software that aids cancer treatments by identifying that difference between normal cells and cancer cells. [18] De Souza and Devabhaktuni Srikrishna also co-authored the book Cancer: What a Personal Crisis Taught Us About How T-Cells Can Save Your Life. [19]

Bibliography

Related Research Articles

<span class="mw-page-title-main">AstraZeneca</span> British pharmaceutical company

AstraZeneca plc is a British-Swedish multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, England. It has a portfolio of products for major diseases in areas including oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation. It has been involved in developing the Oxford–AstraZeneca COVID-19 vaccine.

<span class="mw-page-title-main">George Church (geneticist)</span> American geneticist

George McDonald Church is an American geneticist, molecular engineer, chemist, serial entrepreneur, and pioneer in personal genomics and synthetic biology. He is the Robert Winthrop Professor of Genetics at Harvard Medical School, Professor of Health Sciences and Technology at Harvard University and Massachusetts Institute of Technology, and a founding member of the Wyss Institute for Biologically Inspired Engineering at Harvard. Through his Harvard lab Church has co-founded around 50 biotech companies pushing the boundaries of innovation in the world of life sciences and making his lab as a hotbed of biotech startup activity in Boston. In 2018, the Church lab at Harvard made a record by spinning off 16 biotech companies in one year. The Church lab works on research projects that are distributed in diverse areas of modern biology like developmental biology, neurobiology, info processing, medical genetics, genomics, gene therapy, diagnostics, chemistry & bioengineering, space biology & space genetics, and ecosystem. Research and technology developments at the Church lab have impacted or made direct contributions to nearly all "next-generation sequencing (NGS)" methods and companies. In 2017, Time magazine listed him in Time 100, the list of 100 most influential people in the world. In 2022, he was featured among the most influential people in biopharma by Fierce Pharma, and was listed among the top 8 famous geneticists of all time in human history. As of January 2023, Church serves as a member of the Bulletin of the Atomic Scientists' Board of Sponsors, established by Albert Einstein.

Agenus Inc. is a Lexington, Massachusetts-based biotechnology company focused on immunotherapy including immuno-oncology, a field that uses the immune system to control or cure cancer. The company is developing checkpoint modulators (CPMs), patient-specific anti-cancer vaccines, and adjuvants desugned for use with various vaccines. CPM development is a particularly fast-moving field, since early products have produced unprecedented clinical benefits for patients.

Illumina, Inc. is an American biotechnology company, headquartered in San Diego, California, and it serves more than 140 countries. Incorporated on April 1, 1998, Illumina develops, manufactures, and markets integrated systems for the analysis of genetic variation and biological function. The company provides a line of products and services that serves the sequencing, genotyping and gene expression, and proteomics markets.

Zedo is a US and India-based advertising technology company that provides several online advertising products and services to Internet publishers, advertisers, and agencies. The company was founded in 1999 by Roy de Souza.

<span class="mw-page-title-main">Patrick Soon-Shiong</span> South African and American billionaire physician, CEO & philanthropist (b. 1952)

Patrick Soon-Shiong is a South African-American transplant surgeon, billionaire businessman, bioscientist, and media proprietor. He is the inventor of the drug Abraxane, which became known for its efficacy against lung, breast, and pancreatic cancer. Soon-Shiong is the founder of NantWorks, a network of healthcare, biotech, and artificial intelligence startups; an adjunct professor of surgery and executive director of the Wireless Health Institute at the University of California, Los Angeles; and a visiting professor at Imperial College London and Dartmouth College. Soon-Shiong has published more than 100 scientific papers and has more than 230 issued patents worldwide on advancements spanning numerous fields in technology and medicine.

CancerVax was an American pharmaceutical company founded in 1998 by Donald Morton. The company sought to develop a vaccine for cancer, and had candidates for melanoma reach phase III clinical trials. When those trials proved unsuccessful in 2005, the company soon underwent a reverse takeover with Micromet.

<span class="mw-page-title-main">Avax Technologies</span> American biotechnology company

Avax Technologies, Inc is a Philadelphia-based biotechnology company whose most advanced product candidate is MVax for melanoma. MVax is a cancer vaccine that received a Special Protocol Assessment agreement with the FDA in October 2006, and subsequently began a Phase III registration clinical trial in November 2007. In previous studies, MVax demonstrated a 5-year overall survival rate (OS)of 44% and response rate of 35%.

Biovest International, Inc was a Minneapolis-based biotechnology company. Their active immunotherapy, BiovaxID, is a cancer vaccine whose first indication was intended to be consolidation/adjuvant therapy of follicular Non-Hodgkin's Lymphoma. Biovest filed to reorganize under chapter 11 bankruptcy in 2014, BiovaxID was refused European marketing authorization in 2015, and Biovest's stock listing was revoked in 2017.

<span class="mw-page-title-main">Moderna</span> American biotechnology company

NantOmics is a biotechnology company based in Culver City, California, which provides molecular diagnostic products for personalized cancer treatment. It is part of the NantWorks network, a corporation consisting of different startups in the medical and health industry.

Individualized medicine tailors treatment to a single patient. The term refers to an individual, truly personalized medicine that strives to treat each patient on the basis of his own individual biology.

The mutanome is the entirety of somatic cancer mutations in an individual tumor.

Individualized cancer immunotherapy, also referred to as individualized immuno-oncology, is a novel concept for therapeutic cancer vaccines that are truly personalized to a single individual.

Edward F. Fritsch is a scientist in the field of molecular biology and cancer immunology.

<span class="mw-page-title-main">Uğur Şahin</span> German oncologist and immunologist (born 1965)

Uğur Şahin is a German oncologist and immunologist. He is the founder and CEO of BioNTech, which developed one of the major vaccines against COVID-19. His main fields of research are cancer research and immunology.

<span class="mw-page-title-main">Özlem Türeci</span> German physician, scientist and entrepreneur

Özlem Türeci is a German physician, scientist and entrepreneur. In 2008, she co-founded the biotechnology company BioNTech, which in 2020 developed the first messenger RNA-based vaccine approved for use against COVID-19. Türeci has served as BioNTech's chief medical officer since 2018. Since 2021, she has been Professor of Personalized Immunotherapy at the Helmholtz Institute for Translational Oncology (HI-TRON) and Johannes Gutenberg University Mainz. Türeci and her spouse, Uğur Şahin, have won a number of awards.

<span class="mw-page-title-main">Aisha de Sequeira</span> Goan banker (1969–2020)

Julia Maria Aisha de Sequeira was an Indian banker. She was the co-head of Morgan Stanley India from 2013 through 2020. In 2007, she became the founding head of investment banking for Morgan Stanley India, and continued in this position until her death in 2020.

Transgene S.A. is a French biotechnology company founded in 1979. It is based in Illkirch-Graffenstaden, near Strasbourg, and develops and manufactures immunotherapies for the treatment of cancer.

References

  1. 1 2 3 4 5 "Meet Roy de Souza, the tech entrepreneur who turned personal crisis into war against cancer". Moneycontrol. 20 June 2019.
  2. 1 2 3 "How A Tech Entrepreneur Turned a Personal Crisis Into A War Against Cancer". YPO. August 13, 2019.
  3. 1 2 "Home". TEDx2022.
  4. ↑ "Goan Voice UK: supplement on Royde Souza". www.goanvoice.org.uk.
  5. ↑ https://nulta.net/2019/03/car-t-cells-new-hope-for-cancer-therapy/
  6. ↑ Otlacan, Otilia (July 12, 2011). "Interview: Zedo CEO Roy de Souza Discusses Ad Exchanges in the Current Marketplace". Ad Tech Daily.
  7. ↑ "Customer Success Stories: Case Studies, Videos, Podcasts, Innovator stories". Amazon Web Services, Inc.
  8. ↑ Staff Writer. "Got Roomfuls of Stuff? Now Sites Will Help Keep Track of It". Gainesville Sun.
  9. ↑ Rosenbloom, Stephanie (September 17, 2006). "A Sense of Belonging Among Belongings". The New York Times– via NYTimes.com.
  10. ↑ "If We Build It, We Will Come: Unleash the Power of Crowds in Your Business | Zebo.com | InformIT". www.informit.com.
  11. ↑ "Zedo founder launches online exchange". www.ciol.com. 6 October 2011.
  12. ↑ "Zedo To Spin Off Online Ad Exchange Platform Zinc In India". Techcircle. October 14, 2011.
  13. ↑ Saxena, Anupam (October 17, 2011). "Updated: Zedo To Spin-Off Indian Unit; Not To Form JV With Ad Agency".
  14. ↑ "Discovery, Inc acquires assets of ZEDO".
  15. ↑ "Discovery, Inc. acquires assets of ad-tech co ZEDO". www.thehindubusinessline.com. December 8, 2021.
  16. ↑ "Discovery acquires Zedo's assets". Campaign India.
  17. ↑ Krishnan, Revathi (December 11, 2020). "Aisha de Sequeira — 'daughter of Goa' & Morgan Stanley India co-head who idolised Steve Jobs".
  18. ↑ "BreakBio". forcefamilyoffice.org.
  19. ↑ De Souza, R. & Srikrishna, D. (2019). Cancer: What a personal crisis taught us about how T-cells can save your life. BreakBio Corp. ISBN   9780578548777
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.